Hemogenyx Raises £118,632 Through Warrant Exercise and Expands Share Capital

HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has shared an update.

Hemogenyx Pharmaceuticals has received notices to exercise warrants over 50,841 new ordinary shares at prices between 180p and 350p, raising £118,632 in fresh capital. The new shares will be admitted to the FCA’s Official List and to trading on the LSE main market, increasing the company’s issued share capital and voting rights base to 6,425,429 shares.

Following admission of the warrant shares, investors are advised to use the new total share count as the reference point for disclosure obligations under the FCA’s transparency rules. The modest equity increase slightly strengthens Hemogenyx’s balance sheet and may support ongoing development of its clinical-stage programmes while marginally diluting existing shareholders’ stakes.

The most recent analyst rating on (GB:HEMO) stock is a Hold with a £725.00 price target. To see the full list of analyst forecasts on HemoGenyx Pharmaceuticals Plc stock, see the GB:HEMO Stock Forecast page.

Spark’s Take on GB:HEMO Stock

According to Spark, TipRanks’ AI Analyst, GB:HEMO is a Neutral.

The score is held down primarily by very weak financial performance (no revenue, ongoing losses and cash burn, and higher balance-sheet risk from lower equity and increased leverage). Technicals provide some offset with strong recent momentum, but overbought indicators add near-term risk, and valuation support is limited due to a negative P/E and no dividend yield.

To see Spark’s full report on GB:HEMO stock, click here.

More about HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals plc is a London-headquartered, clinical-stage biopharmaceutical company listed on the LSE under the ticker HEMO. Through its U.S. subsidiaries in New York City, the group develops novel medicines, product candidates, and platform technologies focused on treating blood and autoimmune diseases, targeting significant unmet medical needs in these therapeutic areas.

Average Trading Volume: 44,493

Technical Sentiment Signal: Buy

Current Market Cap: £61.45M

Learn more about HEMO stock on TipRanks’ Stock Analysis page.